ImmunoThera

Executive Summary

ImmunoThera is a private biopharmaceutical company advancing novel immunotherapies and vaccines for infectious diseases and oncology. Leveraging proprietary adjuvant and delivery technologies, the company aims to enhance immune responses against pathogens and tumors. Founded in 2014 and based in Pittsburgh, ImmunoThera has raised $135 million to date and is currently in Phase 1 development. The company’s pipeline includes prophylactic vaccines and therapeutic immune modulators, though specific candidates are not publicly detailed. With a focus on addressing high unmet needs, ImmunoThera has the potential to differentiate in the competitive immuno-oncology and vaccine landscapes. The company’s progress through Phase 1 and its robust financial backing position it for key milestones in the near term. However, as a private, early-stage entity, its valuation and long-term trajectory remain uncertain. Continued execution on clinical trials and strategic partnerships will be critical to advancing its platform.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 data readout for lead infectious disease vaccine candidate60% success
• Q4 2026IND filing for first oncology immunotherapy candidate50% success
• H2 2026Strategic partnership announcement for adjuvant technology platform45% success